Myotonic dystrophy mouse models: towards rational therapy development.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Trends in Molecular Medicine

• Publication date

  2011-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molmed.2011.05.004PMID 21724467PMCID PMC3881009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland

  2011cited by this paper
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

  2011cited by this paper
• Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

  2010cited by this paper
• Muscleblind1, but Not Dmpk or Six5, Contributes to a Complex Phenotype of Muscular and Motivational Deficits in Mouse Models of Myotonic Dystrophy

  2010cited by this paper
• Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells

  2010cited by this paper
• Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients

  2010cited by this paper
• Mechanisms of trinucleotide repeat instability during human development

  2010cited by this paper
• CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.

  2010cited by this paper
• Inactivation of hnRNP K by Expanded Intronic AUUCU Repeat Induces Apoptosis Via Translocation of PKCδ to Mitochondria in Spinocerebellar Ataxia 10

  2010cited by this paper
• Mechanisms of trinucleotide repeat instability during human development

  2010cited by this paper
• Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

  2010cited by this paper
• Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy

  2010cited by this paper
• Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway.

  2010cited by this paper
• Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients.

  2010cited by this paper
• Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2

  2010cited by this paper
• Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2

  2010cited by this paper
• Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice

  2009cited by this paper
• Absence of a differentiation defect in muscle satellite cells from DM2 patients.

  2009cited by this paper
• Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA

  2009cited by this paper
• Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy

  2009cited by this paper
• Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides

  2009cited by this paper
• Pentamidine reverses the splicing defects associated with myotonic dystrophy

  2009cited by this paper
• Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients.

  2009cited by this paper
• PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.

  2009cited by this paper
• Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene

  2009cited by this paper
• Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.

  2009cited by this paper
• RNA Gain-of-Function in Spinocerebellar Ataxia Type 8

  2009cited by this paper
• Myotonic Dystrophy Transgenic Mice Exhibit Pathologic Abnormalities in Diaphragm Neuromuscular Junctions and Phrenic Nerves

  2008cited by this paper
• Muscleblind‐like 2 (Mbnl2) ‐deficient mice as a model for myotonic dystrophy

  2008cited by this paper
• RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression

  2008cited by this paper
• A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart

  2008cited by this paper
• Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy

  2008influential reference
• Cytoplasmic CUG RNA Foci Are Insufficient to Elicit Key DM1 Features

  2008cited by this paper
• Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.

  2007cited by this paper
• Cerebral involvement in myotonic dystrophies

  2007cited by this paper
• DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice.

  2007cited by this paper
• Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.

  2007cited by this paper
• Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

  2007cited by this paper
• Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy.

  2007cited by this paper
• Muscle Chloride Channel Dysfunction in Two Mouse Models of Myotonic Dystrophy

  2007cited by this paper
• Haploinsuffciency for Znf9 in Znf9+/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy.

  2007cited by this paper
• CTG Trinucleotide Repeat “Big Jumps”: Large Expansions, Small Mice

  2007influential reference
• Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1.

  2007cited by this paper
• Chemical modifiers of unstable expanded simple sequence repeats: what goes up, could come down.

  2006cited by this paper
• Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.

  2006influential reference
• DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression.

  2006cited by this paper
• Protein composition of the intranuclear inclusions of FXTAS.

  2006cited by this paper
• Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2.

  2006cited by this paper
• Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

  2006cited by this paper
• Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy

  2006influential reference
• Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy.

  2005cited by this paper
• Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy

  2005cited by this paper
• PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.

  2005cited by this paper
• RNA CUG-binding Protein 1 Increases Translation of 20-kDa Isoform of CCAAT/Enhancer-binding Protein β by Interacting with the α and β Subunits of Eukaryotic Initiation Translation Factor 2*

  2005cited by this paper
• FMR1 RNA within the Intranuclear Inclusions of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

  2004cited by this paper
• Six5 is required for spermatogenic cell survival and spermiogenesis.

  2004cited by this paper
• Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy.

  2004cited by this paper
• Chemotherapeutic deletion of CTG repeats in lymphoblast cells from DM1 patients.

  2004cited by this paper
• Overexpression of CUG Triplet Repeat-binding Protein, CUGBP1, in Mice Inhibits Myogenesis*

  2004cited by this paper
• RNA Leaching of Transcription Factors Disrupts Transcription in Myotonic Dystrophy

  2004cited by this paper
• Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR.

  2004cited by this paper
• Chemically induced increases and decreases in the rate of expansion of a CAG*CTG triplet repeat.

  2004cited by this paper
• A Muscleblind Knockout Model for Myotonic Dystrophy

  2003influential reference
• Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum.

  2003cited by this paper
• Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.

  2002cited by this paper
• Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.

  2002cited by this paper
• Characterization of Cardiac Conduction System Abnormalities in Mice with Targeted Disruption of Six5 Gene

  2002cited by this paper
• Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.

  2002cited by this paper
• Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins.

  2002cited by this paper
• Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9

  2001cited by this paper
• Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy

  2001cited by this paper
• Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities.

  2001influential reference
• SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia.

  2001cited by this paper
• Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.

  2001cited by this paper
• Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

  2000cited by this paper
• Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts

  2000cited by this paper
• Dramatic, expansion-biased, age-dependent, tissue-specific somatic mosaicism in a transgenic mouse model of triplet repeat instability.

  2000cited by this paper
• Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy

  2000cited by this paper
• Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability.

  2000influential reference
• Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy

  2000cited by this paper
• CUG repeat binding protein (CUGBP1) interacts with the 5'''' region of C/EBPβ β β β mRNA and regulates translation of C/EBPβ

  1999cited by this paper
• DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model.

  1999cited by this paper
• CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms.

  1999cited by this paper
• Somatic instability of the CTG repeat in mice transgenic for the myotonic dystrophy region is age dependent but not correlated to the relative intertissue transcription levels and proliferative capacities.

  1998cited by this paper
• Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy.

  1998cited by this paper
• Hypermutable myotonic dystrophy CTG repeats in transgenic mice

  1997cited by this paper
• Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene

  1997cited by this paper
• Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice

  1997cited by this paper
• Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP

  1997cited by this paper
• Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice

  1996cited by this paper
• Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.

  1996cited by this paper
• Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy

  1996cited by this paper
• Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues

  1995cited by this paper
• A novel homeodomain-encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat.

  1995cited by this paper
• Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses.

  1995cited by this paper
• Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy.

  1993cited by this paper
• Genomic organization and transcriptional units at the myotonic dystrophy locus.

  1993cited by this paper
• Anticipation in myotonic dystrophy: new light on an old problem.

  1992cited by this paper
• Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

  1992cited by this paper
• Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

  1992cited by this paper

• Patient-derived 3D engineered human muscle model recapitulates CLCN1 mis-splicing and myotonia in myotonic dystrophy type 1

  2026cites this paper
• Disruptions of Cell Signaling Pathways in Myotonic Dystrophy Type 1 (DM1) Skeletal Muscle, their Pathogenic Impact and Potential for Combinatorial Therapeutics.

  2026cites this paper
• Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies

  2025cites this paper
• 284th ENMC International Workshop: Cognitive and behavioral abnormalities in pediatric DM1; what should we measure in preparation for clinical trials? Hoofddorp, The Netherlands, January 24-26 2025.

  2025cites this paper
• Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives

  2025cites this paper
• Repeat length as a key determinant for disease severity and antisense oligonucleotide activity in myotonic dystrophy type 1

  2025cites this paper
• Natural Antioxidants Reduce Oxidative Stress and the Toxic Effects of RNA-CUG(exp) in an Inducible Glial Myotonic Dystrophy Type 1 Cell Model

  2025cites this paper
• Interplay of Spoonbill, Larp7 and survival motor neuron, in Drosophila model of Spinocerebellar Ataxia 8 non-coding RNA associated neurodegeneration

  2025cites this paper
• Myotonic dystrophies: an update on clinical features, molecular mechanisms, management, and gene therapy

  2024cites this paper
• Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1

  2024cites this paper
• Ultrasound Imaging for Assessing Aortic Phenotypes: A Preclinical Tool for Measuring Cardiac Disease Model Progression and Therapeutic Effect

  2024cites this paper
• Slitrk4 is required for the development of inhibitory neurons in the fear memory circuit of the lateral amygdala

  2024cites this paper
• Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1

  2023cites this paper
• Protein Phosphorylation Alterations in Myotonic Dystrophy Type 1: A Systematic Review

  2023cites this paper
• Myotonic Dystrophy Type 1: A Comprehensive Literary Review

  2023influential citation
• Physiotherapeutic Protocol and ZnO Nanoparticles: A Combined Novel Treatment Program against Bacterial Pyomyositis

  2022cites this paper
• Genetically modified animal models of hereditary diseases for testing of gene-directed therapy

  2022cites this paper
• Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene

  2021cites this paper
• Integrative Proteogenomics for Differential Expression and Splicing Variation in a DM1 Mouse Model

  2021cites this paper
• Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies

  2021cites this paper
• Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients

  2021cites this paper
• Bioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle

  2021cites this paper
• The Development of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disorders

  2020cites this paper
• In Vivo Genome Engineering for the Treatment of Muscular Dystrophies

  2020cites this paper
• The contribution of human pluripotent stem cells to the study of myotonic dystrophy type 1

  2020cites this paper
• The myotonic dystrophies

  2020cites this paper
• Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice

  2019cites this paper
• Abnormal nuclear aggregation and myotube degeneration in myotonic dystrophy type 1

  2019cites this paper
• Gene Therapy and Gene Editing for Myotonic Dystrophy

  2019cites this paper
• Transplantation studies reveal internuclear transfer of toxic RNA in engrafted muscles of myotonic dystrophy 1 mice

  2019cites this paper
• Beyond Borders: Myotonic Dystrophies – A European Perception

  2019cites this paper
• Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1

  2019cites this paper
• Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9

  2018cites this paper
• The Regulative Nature of Mammalian Embryos.

  2018cites this paper
• RBFOX 1 Cooperates with MBNL 1 to Control Splicing in Muscle , Including Events Altered in Myotonic Dystrophy Type 1

  2018cites this paper
• Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy

  2018cites this paper
• Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1

  2018cites this paper
• Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing.

  2018cites this paper
• Myotonic Dystrophy and Developmental Regulation of RNA Processing.

  2018cites this paper
• Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy

  2018cites this paper
• Deregulation of RNA Metabolism in Microsatellite Expansion Diseases.

  2018cites this paper
• The flash-small-pool PCR: how to transform blotting and numerous hybridization steps into a simple denatured PCR.

  2018cites this paper
• Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies

  2018cites this paper
• Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds

  2017cites this paper
• Splicing Analysis of a Myotonic Dystrophy Type 1 Mouse Model Treated with Small Molecules

  2017cites this paper
• Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS

  2017cites this paper
• CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients

  2017cites this paper
• Epigenetics of the myotonic dystrophy-associated DMPK gene neighborhood

  2016cites this paper
• Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy

  2016cites this paper
• Modified Antisense Oligonucleotides and Their Analogs in Therapy of Neuromuscular Diseases

  2016cites this paper
• A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle

  2016influential citation
• Restricting calcium currents is required for correct fiber type specification in skeletal muscle

  2016cites this paper
• Cell Membrane Integrity in Myotonic Dystrophy Type 1: Implications for Therapy

  2015cites this paper
• Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development

  2015cites this paper
• Transgenesis and Genome Manipulations

  2015cites this paper
• Chapter 37 – Myotonic Dystrophy

  2015cites this paper
• Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.

  2015cites this paper
• Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

  2015cites this paper
• A Translational Pathway Toward a Clinical Trial Using the Second-Generation AAV Micro Dystrophin Vector

  2015cites this paper
• Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy Type 1 Induced Pluripotent Stem Cell‐Derived Neural Stem Cells

  2015cites this paper
• Workshop Report: consensus on biomarkers of cerebral involvement in myotonic dystrophy, 2–3 December 2014, Milan, Italy

  2015cites this paper
• Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics

  2015cites this paper
• Muscle wasting in myotonic dystrophies: a model of premature aging

  2015cites this paper
• Macular dystrophies mimicking age-related macular degeneration.

  2014cites this paper
• Genetics of the Mouse

  2014cites this paper
• MBNL proteins and their target RNAs, interaction and splicing regulation

  2014cites this paper
• Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

  2014cites this paper
• Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2

  2014cites this paper
• RNA-protein interactions in unstable microsatellite diseases.

  2014influential citation
• RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1

  2014cites this paper
• Illuminating CNS and cognitive issues in myotonic dystrophy: Workshop report.

  2013cites this paper
• RNA toxicity in human disease and animal models: from the uncovering of a new mechanism to the development of promising therapies.

  2013cites this paper
• Transcriptionally Repressive Chromatin Remodelling and CpG Methylation in the Presence of Expanded CTG-Repeats at the DM1 Locus

  2013cites this paper
• Molecular Genetic Basis of Myotonic Dystrophy

  2013cites this paper
• Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes

  2013cites this paper
• Generation of Neural Cells from DM1 Induced Pluripotent Stem Cells As Cellular Model for the Study of Central Nervous System Neuropathogenesis

  2013cites this paper
• Age‐dependent chloride channel expression in skeletal muscle fibres of normal and HSALR myotonic mice

  2013cites this paper
• A Novel CUGexp·MBNL1 Inhibitor with Therapeutic Potential for Myotonic Dystrophy Type 1

  2013cites this paper
• Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice

  2013cites this paper
• Myotonic Dystrophies Type 1 and 2

  2013cites this paper
• In vivo strategies for drug discovery in myotonic dystrophy disorders.

  2013cites this paper
• Altered Replication in Human Cells Promotes DMPK (CTG)n · (CAG)n Repeat Instability

  2012cites this paper
• Epigenetic Alterations in Muscular Disorders

  2012cites this paper
• Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy

  2012cites this paper
• Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1,000 CTG Repeats from the Human DM1 Locus

  2012cites this paper
• Animal models of muscular dystrophy.

  2012cites this paper
• From dynamic combinatorial ‘hit’ to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy

  2012cites this paper
• Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts.

  2012cites this paper
• The myotonic dystrophies: molecular, clinical, and therapeutic challenges.

  2012cites this paper
• Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges.

  2011cites this paper
• In Vivo Evaluation of CTG Repeat-Affected Muscle Pathology in a Myotonic Dystrophy Model Mouse Using Electromyography and Fluorescence In Situ Hybridization.

  year unknowncites this paper